Thanks, BJ for the modafinil analysis.
While we have you in an expansive mood, any comments on REGN's Axokine? It just entered human trials.
Another obesity candidate of interest to me is SEPR's improved version of Meridia. Not much is known about it other than that they seem awfully excited about it, and it seems to avoid many of Meridia's side-effects.
From their recent 10K (which of course doesn't reflect the excitement):
(+)-desmethylsibutramine, a single-isomer metabolite form of
Meridia(R). Meridia is marketed by Knoll Pharmaceutical Co., a division of BASF AG, for the treatment of obesity. The Company has initiated an exploratory program and its preclinical studies have suggested that (+)-desmethylsibutramine is a potent seritonin, norepinephrine and dopamine reuptake inhibitor. While further extensive studies and clinical work are needed, this triple mode of action may make (+)- desmethylsibutramine an antidepressant drug that offers potential benefit in the treatment of chronic pain syndromes, obesity, attention deficit disorders, anxiety and stress urinary incontinence. Sepracor intends to submit an IND and initiate Phase I clinical trials with (+)-desmethylsibutramine in 1999.
However, I'm always a little cautious about drugs that cure both the common cold and cancer at the same time. <G>
Here's a good sibutramine link:
rxlist.com
Peter |
